Search results
Results From The WOW.Com Content Network
Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.
The risks described in a risk management plan fall into one of three categories: identified risks, potential risks, and unknown risks. Also described within a risk management plan are the measures that the Market Authorization Holder, usually a pharmaceutical company, will undertake to minimize the risks associated with the use of the drug.
This was the first time that pharmaceutical companies were questioned about their waste disposal methods. "No federal regulations or laws were created as a result of the hearing." [ citation needed ] "Between the years of 1970-2018 more than 3000 pharmaceutical chemicals were manufactured, but only 17 are screened or tested for in waterways."
China supplies the U.S. with approximately 30 percent of its active pharmaceutical ingredients, the raw ingredients found in medicines that make them function, according to the American Hospital ...
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new tariffs on Chinese imports, as they join big pharma lobbyists who have ...
In the meantime, the healthcare industry is already bracing itself for the president’s new 10% levy on goods from China, where much of the globe’s pharmaceutical production is based.
Pharmaceutical drugs have various known and unknown effects on the environment.. The term environmental persistent pharmaceutical pollutants (EPPP) was first suggested in the nomination in 2010 of pharmaceuticals and environment as an emerging issue in a Strategic Approach to International Chemicals Management [1] by the International Society of Doctors for the Environment (ISDE).